Business Wire

Global Dermatology Partnering Deal Trends, Players and Financials Analysis Report 2015-2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Dermatology Partnering 2015-2022: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering.

The Global Dermatology Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 750 dermatology deals.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive dermatology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Dermatology deals.

The report presents financial deal terms values for Dermatology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

In addition, a comprehensive appendix is provided with each report of all dermatology partnering deals signed and announced since 2015. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in dermatology partnering and dealmaking since 2015.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of dermatology technologies and products.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The report includes deals for the following indications: Acne, Actinic keratosis, Angioedema, Burns, Cellulitis, Cosmetics, Dermatitis, Diabetic foot ulcer, Eczema, Hair disorders, Alopecia, Impetigo, Itching, Nail disorders, Psoriasis, Rosacea, Scabies, Sun damage, Rash, Scar, Venous ulcer, Verruca, Wound healing, Wrinkles, plus other dermatology indications.

Report scope

Global Dermatology Partnering 2015-2022 includes:

  • Trends in dermatology dealmaking in the biopharma industry since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to over 750 dermatology deal records
  • The leading dermatology deals by value since 2015

In Global Dermatology Partnering 2015-2022, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Dermatology dealmaking

2.1. Introduction

2.2. Dermatology partnering over the years

2.3. Dermatology partnering by deal type

2.4. Dermatology partnering by industry sector

2.5. Dermatology partnering by stage of development

2.6. Dermatology partnering by technology type

2.7. Dermatology partnering by therapeutic indication

Chapter 3 – Financial deal terms for Dermatology partnering

3.1. Introduction

3.2. Disclosed financials terms for Dermatology partnering

3.3. Dermatology partnering headline values

3.4. Dermatology deal upfront payments

3.5. Dermatology deal milestone payments

3.6. Dermatology royalty rates

Chapter 4 – Leading Dermatology deals and dealmakers

4.1. Introduction

4.2. Most active in Dermatology partnering

4.3. List of most active dealmakers in Dermatology

4.4. Top Dermatology deals by value

Chapter 5 – Dermatology contract document directory

5.1. Introduction

5.2. Dermatology partnering deals where contract document available

Chapter 6 – Dermatology dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by Dermatology therapeutic target

Appendices

Appendix 1 – Directory of Dermatology deals by company A-Z 2015 to 2022

Appendix 2 – Directory of Dermatology deals by deal type 2015 to 2022

Appendix 3 – Directory of Dermatology deals by stage of development 2015 to 2022

Appendix 4 – Directory of Dermatology deals by technology type 2015 to 2022

For more information about this report visit https://www.researchandmarkets.com/r/z984u0

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Comment moderation is enabled. Your comment may take some time to appear.

Back to top button

Adblock detected

Please consider supporting us by disabling your ad blocker